Literature DB >> 6311322

Efficacy of vaccine Ac NFU1 (S-) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis.

C B Woodman, A Buchan, A Fuller, C Hartley, G R Skinner, D Stocker, D Sugrue, J C Clay, G Wilkins, C Wiblin.   

Abstract

A subunit antigenoid vaccine, Ac NFU1 (S-) MRC 5, was used in patients who had had a clinical episode of herpes genitalis. The rate of recurrence was compared with that in unvaccinated patients to determine the efficacy of vaccination in preventing recurrence and spread of the virus in the community. Seven of 22 (31%) vaccinated patients had eight recurrences after the initial clinical episode; in contrast there were 51 recurrences in 17 of 20 (85%) unvaccinated patients. Although further studies are needed, the results indicate that the vaccine may prevent recurrent episodes of herpes genitalis and thereby reduce the dissemination of this virus in the population.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311322      PMCID: PMC1046215          DOI: 10.1136/sti.59.5.311

Source DB:  PubMed          Journal:  Br J Vener Dis        ISSN: 0007-134X


  7 in total

1.  Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection.

Authors:  G R Skinner; D R Williams; A Buchan; J Whitney; M Harding; K Bodfish
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

2.  Herpes simplex viruses: discrimination of types and correlation between different characteristics.

Authors:  G Plummer; C R Goodheart; M Miyagi; G R Skinner; M E Thouless; P Wildy
Journal:  Virology       Date:  1974-07       Impact factor: 3.616

3.  Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.

Authors:  G R Skinner; C B Woodman; C E Hartley; A Buchan; A Fuller; J Durham; M Synnott; J C Clay; J Melling; C Wiblin; J Wilkins
Journal:  Br J Vener Dis       Date:  1982-12

4.  The preparation, efficacy and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects.

Authors:  G R Skinner; A Buchan; C E Hartley; S P Turner; D R Williams
Journal:  Med Microbiol Immunol       Date:  1980       Impact factor: 3.402

5.  Incidence of herpes simplex virus types 1 and 2 isolated in patients with herpes genitalis in Sheffield.

Authors:  I G Barton; G R Kinghorn; S Najem; L S Al-Omar; C W Potter
Journal:  Br J Vener Dis       Date:  1982-02

6.  Proteins specified by herpes simplex virus. XII. The virion polypeptides of type 1 strains.

Authors:  J W Heine; R W Honess; E Cassai; B Roizman
Journal:  J Virol       Date:  1974-09       Impact factor: 5.103

7.  The relative infrequency and low levels of neutralising and immunoprecipitating antibody to herpes simplex viruses types 1 and 2 in patients with a history of recurrent herpes genitalis.

Authors:  C B Woodman; D Stocker; D Sugrue; M Desberbasques; C E Hartley; A Fuller; A Buchan; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1983       Impact factor: 3.402

  7 in total
  1 in total

1.  Herpes vaccine.

Authors:  A Mindel
Journal:  Br J Vener Dis       Date:  1984-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.